Ninlaro (Ixazomib Citrate)

Ninlaro is a proteasome inhibitor used in the treatment of multiple myeloma, either as initial therapy or in relapsed/refractory disease.

• Multiple myeloma (initial therapy): improves progression‑free survival when combined with lenalidomide and dexamethasone.
• Multiple myeloma (relapsed/refractory): provides an oral option that can extend disease control in patients who have received prior therapies.
• Multiple myeloma (maintenance): may be used as part of a maintenance regimen to sustain response after induction therapy.

• Ixazomib citrate reversibly inhibits the 20S proteasome, preventing the degradation of polyubiquitinated proteins. This leads to accumulation of misfolded proteins within malignant plasma cells, triggering endoplasmic reticulum stress and ultimately inducing apoptosis of the cancerous cells.

Common side effects are typically mild to moderate and may affect treatment tolerability.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: watery stools, often transient.
• Fatigue: general tiredness or lack of energy.
• Constipation: reduced bowel movements.
• Decreased appetite: reduced desire to eat.
• Peripheral edema: mild swelling of extremities.

Serious or Rare Side Effects

• Neutropenia: low neutrophil count increasing infection risk.
• Thrombocytopenia: reduced platelet count leading to bleeding.
• Severe infections: opportunistic or bacterial infections.
• Pulmonary embolism: blood clot in lung vessels.
• Cardiac failure: reduced heart function.
• Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.

Before initiating therapy, clinicians should assess baseline health status and monitor for specific risks.

• Monitor blood counts: regular CBC to detect neutropenia or thrombocytopenia.
• Assess hepatic function: liver enzymes should be checked prior to and during treatment.
• Evaluate infection risk: screen for active infections and vaccinate when appropriate.
• Use caution in cardiac disease: monitor for signs of heart failure.
• Contraindicated in pregnancy: safety not established; avoid use in pregnant patients.
• Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Ixazomib may interact with other medicines that affect its metabolism or increase toxicity.

Major Interactions (Avoid)

• Strong CYP3A inducers (e.g., rifampin, carbamazepine): may reduce ixazomib exposure.
• Strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin): may increase ixazomib levels.
• Antacids containing aluminum or magnesium: can impair absorption if taken simultaneously.

Moderate Interactions (Monitor Closely)

• Narrow‑therapeutic‑index CYP3A substrates (e.g., tacrolimus, cyclosporine): monitor drug levels.
• Anticoagulants (e.g., warfarin): watch for altered coagulation parameters.
• Immunosuppressants (e.g., mycophenolate): increased risk of infection, monitor closely.